International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

van Rhee, Frits; M. Voorhees, Peter; Dispenzieri, Angela; Fosså, Alexander; Srkalović, Gordan; Ide, Makoto; C. Munshi, Nikhil; Schey, Stephen; Streetly, Matthew; K. Pierson, Sheila; Partridge, Helen; Mukherjee, Sudipto; Shilling, Dustin; Stone, Katie; D Greenway, Amy; R. Ruth, Jason; Jo Lechowicz, Mary; Chandrakasan, Shanmuganathan; Jayanthan, Raj; S. Jaffe, Elaine; A. Leitch, Heather; Pemmaraju, Naveen; Chadburn, Amy; S. Lim, Megan; S.J. Elenitoba‐Johnson, Kojo; P. Krymskaya, Vera; M. Goodman, Aaron; Hoffmann, Christian; Luigi Zinzani, Pier; Ferrero, Simone; Terriou, Louis; Sato, Yasuharu; Simpson, David; Wong, Raymond; Rossi, Jean‐François; D. Nasta, Sunita; Yoshizaki, Kazuyuki; Kurzrock, Razelle; S. Uldrick, Thomas; Casper, Corey; Oksenhendler, Éric; C. Fajgenbaum, David

doi:10.1182/blood-2018-07-862334

Public

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Published in Blood • Sep 4, 2018

Authors:

Frits van Rhee

Peter M. Voorhees

Angela Dispenzieri

Abstract

Castleman disease (CD) describes a group of heterogeneous hematologic disorders with characteristic histopathological features. CD can present with unicentric or multicentric (MCD) regions of lymph node enlargement. Some cases of MCD are caused by human herpesvirus-8 (HHV-8), whereas others are HHV-...

Subject

Medicine

Castleman disease

Tocilizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!